The global cell surface markers detection market was valued at USD 4,940.40 million in 2022. It is projected to reach USD 10,380.79 million by 2031, growing at a CAGR of 8.60% during the forecast period (2023-2031). Cell surface markers can be used to differentiate between different types of cells. Cell surface markers—proteins and carbohydrates linked to the cellular membrane—must function to play a crucial part in intercellular signaling. One can recognize a cell and distinguish it from the neighborhood of cells by analyzing the composition of the cell surface indicators present on a particular cell. T cells are classified into cytotoxic, helper, and regulatory T cells using common cell surface markers such as CD3, CD4, CD8, and CD25.
Over the past few decades, interest in using cell surface indicators for therapy, diagnosis, and prognosis has grown. Examining biomarkers in cancer patients during the pre-and post-therapeutic period is necessary to pinpoint specific cell types that increase the likelihood of disease development and subsequent post-therapeutic relapse. Cells must be distinguishable from one another to grasp the myriad interactions. Cell surface indicators can be used to distinguish between the various cell types. Cell surface markers, proteins, and carbohydrates affixed to the cellular membrane are crucial for intercellular signaling.
It is possible to detect and identify the surrounding cell population using the cell surface markers present on a given cell. To distinguish T cells into their cytotoxic, helper, and regulatory T cell subcategories, common cell surface markers like CD3, CD4, CD8, and CD25 are frequently utilized. Determining the existence and number of specific cell types in a sample might influence choices about diagnosis, clinical trial enrollment, drug development, and much more.
Due to expensive instrument investment, the cell surface markers market would encounter challenges throughout the projected period. To research cell surface markers, businesses must invest significantly in equipment and models. Furthermore, it prevents start-ups and small businesses from entering the market to detect cell surface markers. According to the article " How Much Does a Flow Cytometer Cost, " a flow cytometer's cost might vary from USD 100,000 to USD 500,000 depending on the manufacturer, according to the article "How Much Does a Flow Cytometer Cost," which was published in July 2020. Due to the complexity, high expense, and need for clarity surrounding the regulation and reimbursement of cell marker diagnostic procedures, many clinical laboratories would prefer to invest in sophisticated cell marker analysis equipment. Expensive models would hamper the market's predicted expansion.
The cell surface markers present in the cells in a population can be found using various techniques. For instance, immunohistochemistry (IHC), flow cytometry, and RNA sequencing (RNA-Seq) approaches are available to determine the cell surface indicators in a population. The companies in the area are constantly updating their products and launching newer, more advanced ones that are accurate and efficient and can streamline the laboratory workflow through the automation of various previously manually operated and time-consuming procedures. This is due to technological advancements and the miniaturization of multiple technologies/devices used in the healthcare industry.
For instance, Sysmex America Inc. introduced its highly automated XF-1600 flow cytometer in June 2020, giving laboratories better flexibility and productivity. Additionally, according to the company, the XF-1600 can automate antibody staining, incubation, and flow cytometry analysis, ensuring a new level of confidence in the results generated. It also seamlessly integrates with the company's other systems, such as its PS-10 Sample Preparation System.
The global cell surface markers detection market is segmented by product and application.
Based on the product, the global cell surface markers detection market is bifurcated into flow cytometry, hematology analyzers, and others.
The flow cytometry segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.90% during the forecast period. Flow cytometry identifies and quantifies a population of cells or particles' physical and chemical properties. Particles or cells from the sample are suspended in a fluid and introduced into the flow cytometer equipment. It is utilized in protein engineering, cell sorting, cell counting, and biomarker detection. The use of this technology as a clinical laboratory technique has progressed from the detection of cell-surface proteins to the characterization of intracellular proteins and the provision of various approaches to evaluating particular aspects of adaptive and innate immune function.
Despite being a crucial part of medicine, hematology analysis requires complex equipment, expensive chemical reagents, time-consuming procedures, and highly qualified personnel. According to a study published in 2020 titled "Label-free hematology analysis using deep-ultraviolet microscopy," hematological analysis uses variations in blood cell morphology, enumeration, and molecular or cytogenetic properties to screen, diagnose, and monitor a variety of blood conditions and diseases, including allergic and inflammatory reactions, infections, sepsis, immune system disorders, cancers, and more. The abovementioned situation shows that the growth of diseases like cancer, sepsis, immune system problems, and allergic and inflammatory reactions may increase the examined segment.
Using cell imaging tools, it is possible to examine every element of cellular function in real time under routine and experimental conditions. Cell imaging is crucial for drug discovery, optimization, and characterization at the single-cell level, as well as for examining the effects on tissues and organs in animal models. It is also crucial for the basic science that results in the isolation and characterization of the proteins and environmental factors involved in developing the disease. Most imaging in drug research is done on fixed cells because it enables decoupling between image acquisition and cell preparation.
Based on application, the global cell surface markers detection market is bifurcated into disease diagnosis and identification, drug discovery, and others.
The drug discovery segment owns the highest market and is estimated to grow at a CAGR of 8.95% during the forecast period. Cell surface indicators can support the development of new drugs, particularly in personalized medicine. Scientists are starting to progress in developing novel medications thanks to the capacity to recognize individual cells based on surface characteristics. Drugs appropriate for these particular compounds can then be designed once the targets, surface proteins, and carbohydrates have been identified. For instance, brand-new therapeutic targets are being discovered on the surface of cancer cells. The clusters of differentiation serve as new targets for chemotherapeutic medications in addition to being employed for identification.
The growing need for precision medicine, the increased use of diagnostics, and technological advancements related to higher throughput and automation are the main factors propelling the market's expansion. For instance, it has been discovered that lung tumors have approximately 200 cell-surface markers. These include indicators like the EGFR gene mutation and Cytokeratin fragment 21-1. These indicators are employed in diagnostic procedures to identify tumor cells in the blood. The proteins produced on the surface of malignant cells serve as markers of particular tumor types because cell surface indicators act as monograms to aid in identifying and classifying cells. The identification of molecules aids in the diagnosis of diseases. Carina A. Bäuerlein looked into whether the detection of a combination of the expression of T-cell surface markers on peripheral blood (PB) CD8+ T-cells would improve the ability to predict acute graft-versus-host disease in the article "A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease," published in 2021.
Research and academic applications are among the additional applications. The main drivers influencing the growth of this market are the expanding applications of cell surface markers in cancer, stem cell, and HIV research, the rising number of cancer and stem cell research projects globally, and the rising public-private funding for cell surface marker-based research. Government programs and clinical trials related to stem cell research are multiplying, which fosters the industry's expansion. The Australian Government Department of Health introduced the stem cell therapeutics mission in 2019. It is a program for sponsoring scientific research with a USD 150 investment spread over nine years to create novel, secure, and efficient treatments for patients with terminal illnesses.
The global cell surface markers detection market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor and is expected to grow at a CAGR of 8.80% during the forecast period. The United States is anticipated to hold a sizable market share in the North American region over the forecast period in the market under study, primarily because of the high burden of chronic diseases like cancer, cardiovascular diseases, and neurological disorders, among others, as well as the presence of a significant number of research and development facilities across the nation. For instance, the American Cancer Society forecasts that in 2021 there will be an estimated 1,898,160 new instances of cancer identified in the country and 608,570 cancer-related deaths. This figure is likely to rise in the future marginally.
Europe is expected to grow at a CAGR of 8.30% during the forecast period. Germany is one of the most research-intensive nations in the European region, investing heavily in R&D activities. Coupled with the high prevalence of diseases and rising demand for precision medicine, Germany's market for cell surface markers detection is anticipated to expand throughout the study's forecast period. Germany reported 628,519 new cancer cases in 2020, and according to Global Cancer Observatory (Globocan) 2020 data, this number was expected to rise to 749,559 cancer cases by 2040. This represents a significant increase in the country's cancer burden. As a result, the demand for diagnostics and precision medicine is anticipated to rise, propelling the studied market in the country.
Asia-Pacific is expected to grow significantly over the forecast period. Due to factors like rising R&D spending, product launches by major market players, and the expansion of laboratories, the Chinese cell surface markers detection market is anticipated to experience growth over the forecast period. The introduction of new devices into the market also helps it grow. For instance, Thermo Fisher Scientific announced that the Invitrogen Attune CytPix Flow Cytometer would be available in China starting in June 2021. The tool is an imaging-enhanced flow cytometer that combines high-speed imaging with acoustic-focusing flow cytometry technology. In a similar vein, Sysmex Corporation introduced the XS-500ix, an automated hematology analyzer, in China in September 2018. These launches will increase the availability of various devices capable of handling multiple tasks, increasing the number of creative solutions nationwide and spurring market expansion.
Kingdom of Saudi Arabia, Kuwait, Bahrain, Qatar, United Arab Emirates, and Oman are the six Arab nations that comprise the GCC. Due to factors like the rise in disease prevalence and the expansion of research studies in the region, the market for the detection of GCC cell surface markers is predicted to experience significant growth. According to a paper published in April 2020 titled "Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: A systematic review," breast cancer is the common malignancy in each GCC nation, with women there typically receiving a diagnosis earlier than those in the United Kingdom. The region's rising cancer incidence necessitates more diagnoses, which could boost demand for the market under study.
The global cell surface markers detection market's major key players are
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|